36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
